• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Those Sensitive Biotechs

They are prone to being whipsawed by news.
By KATE STALTER Jan 06, 2015 | 12:00 PM EST
Stocks quotes in this article: ILMN, BMR, AZN, ALXN, GILD, CELG, AMGN, BOTA

While NYSE and Nasdaq stocks took a tumble in heavy volume Monday, some companies were impervious to concerns about oil prices or the financial troubles of tiny Mediterranean nations.

Biotechnology stocks frequently move independently of the broader market, or, in technical jargon, they often show a low correlation to indexes. They are often immune to wider concerns about the economy.

Disparate pieces of news affected the biotech industry on Monday.

Illumina (ILMN), whose research processes are used to research diseases and develop drugs and molecular tests in clinical labs, advanced 2.86% in heavier-than-normal volume on Monday, bucking the wider market trend.

The company announced that it would sign a 15-year lease with REIT BioMed Realty Trust (BMR) for a 360,000-square-foot laboratory and office compound in Foster City, California.

A real estate transaction of that magnitude sends a message about a company's future prospects. Earnings and revenue growth at Illumina have been accelerating in recent quarters, and analysts expect earnings to grow 20% this year. 

Illumina has a market cap of $27 billion, but it still has a beta of 1.86, indicating its volatility relative to the broader market. But that lack of correlation within the overall sub-sector of biotech also has, of course, a down side. Frequently, you'll see individual stocks within that industry display sudden price moves, in either direction, in response to company-specific news.

Sometimes, news from pre-IPO companies may bode well for the entire biotech industry.

For example, Moderna Therapeutics, a Massachusetts biotech, raised $450 million from venture capital firms, as well as AstraZeneca (AZN) and Alexion Pharmaceuticals (ALXN).  Moderna specializes in developing experimental drugs in the relatively new area of messenger RNA. Analysts say the capital infusion was one of the largest private biotech investments to date.

Biotech, as a whole, have held up well over the past few months, trading independently of stocks that are more sensitive to the economy, commodity prices, or just the day-to-day news-driven worries.

Large caps, such as Gilead Sciences (GILD), Celgene (CELG), Alexion and Amgen (AMGN) weathered 2014's rough patches fairly well, for the most part. Analysts expect those companies to deliver solid earnings growth for 2014, when they report, and for this year.

Of course, small-cap biotechs can be notoriously volatile. In addition, many trade below $10, making them especially precarious. Unfortunately, many people like to take a flier on these speculative stocks, lured by outsized gains on news of a development such as a successful clinical trial. On the other hand, bad news can sink one of these firms in a heartbeat.

For example, Biota Pharmaceuticals (BOTA), which closed Monday at $2.85, plummeted 34% on April 29, on news that a government-sponsored clinical trial had been canceled.

Because of the potential to be whipsawed by news, these smaller stocks from the biotech sector can be particularly difficult to hold, or even trade.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stalter has no positions in any securities mentioned.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:23 PM EDT STEPHEN GUILFOYLE

    We're Cleaning Out This Retailer From the Bullpen

    Check out the latest moves in TheStreet's Stocks U...
  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login